Evaluation of clinical efficacy and sustainability of COVID-19 booster vaccination in patients with hematological diseases.

Evaluation of clinical efficacy and sustainability of COVID-19 booster vaccination in patients with hematological diseases. - Evaluation of clinical efficacy and sustainability of COVID-19 booster vaccination in patients with hematological diseases.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048764

Enrollment

600

Registered

2022-08-26

Start date

2022-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hematological diseases, who are treated or followed at Aiiku Hospital.

Exclusion criteria

Exclusion criteria: Patients who are judged to be ineligible for the study.

Design outcomes

Primary

Measure	Time frame
Evaluation of SARS-COV2 spike protein seropositivity at 6m, 12m and 18m after booster vaccination.	—

Countries

Japan

Contacts

Public ContactTakeshi Kondo

Aiiku Hospital Blood Disorders Center

kondo@aiiku-hp.or.jp+81-11-563-2211

Outcome results